159 related articles for article (PubMed ID: 28718331)
1. Entinostat for the treatment of breast cancer.
Trapani D; Esposito A; Criscitiello C; Mazzarella L; Locatelli M; Minchella I; Minucci S; Curigliano G
Expert Opin Investig Drugs; 2017 Aug; 26(8):965-971. PubMed ID: 28718331
[TBL] [Abstract][Full Text] [Related]
2. Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells.
Gameiro SR; Malamas AS; Tsang KY; Ferrone S; Hodge JW
Oncotarget; 2016 Feb; 7(7):7390-402. PubMed ID: 26862729
[TBL] [Abstract][Full Text] [Related]
3. Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer.
Torres-Adorno AM; Lee J; Kogawa T; Ordentlich P; Tripathy D; Lim B; Ueno NT
Clin Cancer Res; 2017 Aug; 23(16):4780-4792. PubMed ID: 28465444
[No Abstract] [Full Text] [Related]
4. Entinostat: a promising treatment option for patients with advanced breast cancer.
Connolly RM; Rudek MA; Piekarz R
Future Oncol; 2017 Jun; 13(13):1137-1148. PubMed ID: 28326839
[TBL] [Abstract][Full Text] [Related]
5. A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expression.
Lee J; Bartholomeusz C; Mansour O; Humphries J; Hortobagyi GN; Ordentlich P; Ueno NT
Breast Cancer Res Treat; 2014 Jul; 146(2):259-72. PubMed ID: 24916181
[TBL] [Abstract][Full Text] [Related]
6. Identification of Jun loss promotes resistance to histone deacetylase inhibitor entinostat through Myc signaling in luminal breast cancer.
Tanioka M; Mott KR; Hollern DP; Fan C; Darr DB; Perou CM
Genome Med; 2018 Nov; 10(1):86. PubMed ID: 30497520
[TBL] [Abstract][Full Text] [Related]
7. Functional cooperation of miR-125a, miR-125b, and miR-205 in entinostat-induced downregulation of erbB2/erbB3 and apoptosis in breast cancer cells.
Wang S; Huang J; Lyu H; Lee CK; Tan J; Wang J; Liu B
Cell Death Dis; 2013 Mar; 4(3):e556. PubMed ID: 23519125
[TBL] [Abstract][Full Text] [Related]
8. Entinostat (SNDX-275) for the treatment of non-small cell lung cancer.
Ruiz R; Raez LE; Rolfo C
Expert Opin Investig Drugs; 2015; 24(8):1101-9. PubMed ID: 26098363
[TBL] [Abstract][Full Text] [Related]
9. HDAC inhibitor entinostat restores responsiveness of letrozole-resistant MCF-7Ca xenografts to aromatase inhibitors through modulation of Her-2.
Sabnis GJ; Goloubeva OG; Kazi AA; Shah P; Brodie AH
Mol Cancer Ther; 2013 Dec; 12(12):2804-16. PubMed ID: 24092810
[TBL] [Abstract][Full Text] [Related]
10. Histone Deacetylase Inhibitor Entinostat Inhibits Tumor-Initiating Cells in Triple-Negative Breast Cancer Cells.
Schech A; Kazi A; Yu S; Shah P; Sabnis G
Mol Cancer Ther; 2015 Aug; 14(8):1848-57. PubMed ID: 26037781
[TBL] [Abstract][Full Text] [Related]
11. The antitumor effects of entinostat in ovarian cancer require adaptive immunity.
Smith HJ; McCaw TR; Londono AI; Katre AA; Meza-Perez S; Yang ES; Forero A; Buchsbaum DJ; Randall TD; Straughn JM; Norian LA; Arend RC
Cancer; 2018 Dec; 124(24):4657-4666. PubMed ID: 30423192
[TBL] [Abstract][Full Text] [Related]
12. Histone deacetylase inhibitor entinostat in combination with a retinoid downregulates HER2 and reduces the tumor initiating cell population in aromatase inhibitor-resistant breast cancer.
Schech AJ; Shah P; Yu S; Sabnis GJ; Goloubeva O; Rosenblatt P; Kazi A; Chumsri S; Brodie A
Breast Cancer Res Treat; 2015 Aug; 152(3):499-508. PubMed ID: 26133921
[TBL] [Abstract][Full Text] [Related]
13. Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models.
Shen L; Ciesielski M; Ramakrishnan S; Miles KM; Ellis L; Sotomayor P; Shrikant P; Fenstermaker R; Pili R
PLoS One; 2012; 7(1):e30815. PubMed ID: 22303460
[TBL] [Abstract][Full Text] [Related]
14. Entinostat for treatment of solid tumors and hematologic malignancies.
Knipstein J; Gore L
Expert Opin Investig Drugs; 2011 Oct; 20(10):1455-67. PubMed ID: 21888556
[TBL] [Abstract][Full Text] [Related]
15. Class I histone deacetylase inhibitor suppresses vasculogenic mimicry by enhancing the expression of tumor suppressor and anti-angiogenesis genes in aggressive human TNBC cells.
Maiti A; Qi Q; Peng X; Yan L; Takabe K; Hait NC
Int J Oncol; 2019 Jul; 55(1):116-130. PubMed ID: 31059004
[TBL] [Abstract][Full Text] [Related]
16. Entinostat, a novel histone deacetylase inhibitor is active in B-cell lymphoma and enhances the anti-tumour activity of rituximab and chemotherapy agents.
Frys S; Simons Z; Hu Q; Barth MJ; Gu JJ; Mavis C; Skitzki J; Song L; Czuczman MS; Hernandez-Ilizaliturri FJ
Br J Haematol; 2015 May; 169(4):506-19. PubMed ID: 25712263
[TBL] [Abstract][Full Text] [Related]
17. Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression.
Raha P; Thomas S; Thurn KT; Park J; Munster PN
Breast Cancer Res; 2015 Feb; 17(1):26. PubMed ID: 25848915
[TBL] [Abstract][Full Text] [Related]
18. The histone deacetylase inhibitor Entinostat enhances polymer-mediated transgene expression in cancer cell lines.
Elmer JJ; Christensen MD; Barua S; Lehrman J; Haynes KA; Rege K
Biotechnol Bioeng; 2016 Jun; 113(6):1345-1356. PubMed ID: 26614912
[TBL] [Abstract][Full Text] [Related]
19. Cooperative Immune-Mediated Mechanisms of the HDAC Inhibitor Entinostat, an IL15 Superagonist, and a Cancer Vaccine Effectively Synergize as a Novel Cancer Therapy.
Hicks KC; Knudson KM; Lee KL; Hamilton DH; Hodge JW; Figg WD; Ordentlich P; Jones FR; Rabizadeh S; Soon-Shiong P; Schlom J; Gameiro SR
Clin Cancer Res; 2020 Feb; 26(3):704-716. PubMed ID: 31645354
[TBL] [Abstract][Full Text] [Related]
20. Histone Deacetylase Inhibitors: An Attractive Therapeutic Strategy Against Breast Cancer.
Damaskos C; Garmpis N; Valsami S; Kontos M; Spartalis E; Kalampokas T; Kalampokas E; Athanasiou A; Moris D; Daskalopoulou A; Davakis S; Tsourouflis G; Kontzoglou K; Perrea D; Nikiteas N; Dimitroulis D
Anticancer Res; 2017 Jan; 37(1):35-46. PubMed ID: 28011471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
